Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
Abstract Proteasome inhibitors (PIs) represent the gold standard in the treatment of multiple myeloma. Among PIs, Bortezomib (BTZ) is frequently used as first line therapy, but peripheral neuropathy (PN), occurring approximately in 50% of patients, impairs their life, representing a dose-limiting to...
Guardado en:
Autores principales: | A. Malacrida, S. Semperboni, A. Di Domizio, A. Palmioli, L. Broggi, C. Airoldi, C. Meregalli, G. Cavaletti, G. Nicolini |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5bb52f7cbfd047d0957809e366036543 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka A, et al.
Publicado: (2013) -
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Bortezomib in autoimmune hemolytic anemia and beyond
por: Raffaella Pasquale, et al.
Publicado: (2021) -
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Shansa Pranami E. Jayaweera, et al.
Publicado: (2021)